{"page":{"totalFilteredElements":381},"studies":[{"active":true,"description":"Lenalidomide, Adriamycin, Dexamethasone \n(RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction\n in Newly Diagnosed Multiple Myeloma Followed by Response-adapted \nConsolidation and Lenalidomide Maintance &#8211; A Randomized Multicenter \nPhase III Trial by Deutsche Studiengruppe Multiples Myelom (DSMM XIV)","eudractNumber":"2009-016616-21","id":414,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT01685814","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2012-07-20T12:37:36+02:00","shortTitle":"DSMM XIV","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<b>GMMG HD9/ DSMM XVIII:</b> A randomized phase III trial assessing iberdomide versus iberdomide plus isatuximab maintenance therapy post autologous hematopoietic stem-cell transplantation in patients with newly diagnosed multiple myeloma.","eudractNumber":"2023-507402-13","id":9091,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT06216158","phase":{"id":"ph_9","name":"Phase III"},"recruitmentStart":"2024-04-03T13:12:13+02:00","shortTitle":"DSMM XVIII [GMMG HD9]","therapeutical":true,"therapyLines":[{"id":"tl_1","name":"Erstlinie"}]},{"active":true,"description":"<div>A Phase 2 Study to Evaluate Safety and Efficacy of Teclistamab in Combination with</div><div>Daratumumab, Lenalidomide, and Dexamethasone with or without Bortezomib as</div><div>Induction Therapy and Teclistamab in Combination with Daratumumab and</div><div>Lenalidomide as Maintenance Therapy in Participants with Newly Diagnosed Transplant Eligible Multiple Myeloma</div><div><br /></div>","eudractNumber":"2022-001186-12","id":8497,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05695508","phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2022-12-01T15:24:49+01:00","shortTitle":"DSMM XX [GMMG-HD10], MajesTEC-5","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Multizentrisches nationales ITP-Register mit begleitender Bioproben-Sammlung","eudractNumber":null,"id":7914,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-12-06T13:31:24+01:00","shortTitle":"Deutsches Immunthrombo­zytopenie-Register (D.ITP-Register)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Multizentrisches nationales ITP-Register und begleitende Bioproben Sammlung","eudractNumber":null,"id":9648,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-02-02T11:46:17+01:00","shortTitle":"Deutsches Immunthrombo­zytopenie-Register (D.ITP-Register)","therapeutical":false,"therapyLines":[{"id":"tl_5","name":"N/A"}]},{"active":true,"description":"Multizentrisches nationales IPT-Register mit begleitender Bioproben-Sammlung","eudractNumber":null,"id":8560,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_12","name":"N/A"},"recruitmentStart":"2022-10-10T08:26:30+02:00","shortTitle":"Deutsches Immunthrombo­zytopenie-Register (D.ITP-Register)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":4372,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2018-04-06T10:55:50+02:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL- FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Nicht-interventionelles, prospektives Register zu Epidemiologie und Behandlungspraxis bei Marginalzonenlymphomen und follikul&#228;ren Lymphomen&#160;inkl. Biomaterial-Sammlung f&#252;r Patienten mit Marginalzonenlymphom","eudractNumber":null,"id":7900,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2021-02-04T15:27:44+01:00","shortTitle":"Deutsches Register für Marginalzonenlymphome und Follikuläre Lymphome - MZoL-FL Register","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p class=\"MsoNormal\">Deutsches Register f&#252;r Stammzelltransplantationen / EBMT\nRegistry on stem cell transplantation (DRST)</p>","eudractNumber":null,"id":6852,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"},{"id":"leu","name":"Leukämien"},{"id":"leu1","name":"Akute lymphatische Leukämie und Burkitt-Lymphom (ALL)"},{"id":"leu2","name":"Akute myeloische Leukämie (AML)"},{"id":"leu3","name":"Chronische myeloische Leukämie (CML)"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_13","name":"Therapieoptimierung"},"recruitmentStart":"2005-01-03T14:01:16+01:00","shortTitle":"Deutsches Register für Stammzelltransplantationen - MZoL-FL Register / EBMT Registry on stem cell transplantation","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Durvalumab (MEDI4736) in combination with consolidative radiochemotherapy and ablative stereotactic radiotherapy in extensive stage SCLC (DuCoRa-SCLC)","eudractNumber":"2022-001822-31","id":10150,"indications":[{"id":"lun","name":"Lungentumoren"},{"id":"lun1","name":"Kleinzelliges Bronchialkarzinom (SCLC)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_7","name":"Phase II"},"recruitmentStart":"2025-01-07T08:54:18+01:00","shortTitle":"DuCoRa-SCLC","therapeutical":true,"therapyLines":[{"id":"tl_5","name":"N/A"}]}]}